首页> 外文OA文献 >Outcome of a Low-Cost Glaucoma Implant versus the Baerveldt Glaucoma Implant for Paediatric Glaucoma in a Tertiary Hospital in Egypt
【2h】

Outcome of a Low-Cost Glaucoma Implant versus the Baerveldt Glaucoma Implant for Paediatric Glaucoma in a Tertiary Hospital in Egypt

机译:低成本的青光眼植入物的结果与Baerveldt glaucoma植入物植入于埃及的一家高级医院的儿科青光眼

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. To compare safety and efficacy between a low-cost glaucoma drainage device (GDD), the Aurolab aqueous drainage implant (AADI), and the Baerveldt glaucoma implant (BGI) in refractory childhood glaucoma in Egypt. Methods. This is a retrospective study of patients who received either an AADI or BGI at a tertiary care postgraduate teaching institute. Children aged <16 years with uncontrolled intraocular pressure (IOP) with or without prior failed trabeculectomy who completed a minimum 6-month follow-up were included. The outcome measures were IOP reduction from preoperative values and postoperative complications. Results. Charts of 57 children (younger than 16 years old) diagnosed with refractory childhood glaucoma were included. Of these, 27 eyes received AADI implants (group A), while 30 received BGI implants (group B). The mean preoperative baseline IOP was 34 ± 5 mmHg in group A versus 29 ± 2 mmHg in group B (p=0.78) in patients on maximum allowed glaucoma medications. In group A versus group B, the mean IOP decreased to 13.25 ± 8.74 mmHg (p=0.6), 12.8 ± 5.4 mmHg (p=0.7), and 12.6 ± 5.6 mmHg (p=0.9) after 1 week, 3 months, and 6 months, respectively. However, in group A, an anterior chamber reaction appeared around the tube in 14 cases starting from the first month and resolved with treatment in only 4 cases. In the other 10 cases, the reaction became more severe and required surgical intervention. This complication was not observed in any eye in group B. Conclusion. AADI, a low-cost glaucoma implant, is effective in lowering IOP in patients with recalcitrant paediatric glaucoma. However, an intense inflammatory reaction with serious consequences developed in some of our patients; we believe these events are related to the valve material. We therefore strongly recommend against its use in children.
机译:目的。在埃及难治儿童青光眼中比较低成本的青光眼引流装置(GDD),Aurolab水性排水植入物(Aadi)和Baerveldt青光眼植入物(BGI)之间的安全性和有效性。方法。这是在第三关节研究生教学研究所收到Aadi或BGI的患者的回顾性研究。包括或没有现有未受控制的人工压力(IOP)的儿童<16岁,含有或没有现有的无效的TRABECULECTOMY,他们完成了至少6个月的随访。结果措施是从术前值和术后并发症的IOP减少。结果。包括诊断有难治性儿童青光眼的57名儿童(年轻比16岁)的图表。其中,27只眼睛接受Aadi植入物(A组),而30则接受BGI植入物(B组)。在最大允许的青光眼药物的患者中,平均术前基线IOP在B组(P = 0.78)中,B组(P = 0.78)中的29±2 mmHg。在A组对B组中,平均IOP降至13.25±8.74mmHg(P = 0.6),12.8±5.4mmHg(P = 0.7),3个月,3个月和3个月后12.6±5.6mmHg(p = 0.9)分别为6个月。然而,在A组中,在第一个月开始的14例中,在管周围出现前室反应,并仅在4例中进行治疗。在另外10例,反应变得更严重和需要外科手术干预。 B组中的任何眼睛都没有观察到这种并发症。结论。 AADI是一种低成本的青光眼植入物,在顽固的儿科青光眼降低IOP方面是有效的。然而,在我们的一些患者中发育严重后果的强烈炎症反应;我们认为这些事件与阀门材料有关。因此,我们强烈建议对儿童使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号